Tivicay (dolutegravir) / ViiV Healthcare 
Welcome,         Profile    Billing    Logout  
 26 Diseases   58 Trials   58 Trials   4692 News 


«12...1516171819202122232425...6263»
  • ||||||||||  Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    Phase classification, Enrollment change:  Rapid HIV Treatment Initiation, Access and Engagement in Care (clinicaltrials.gov) -  Oct 27, 2022   
    P=N/A,  N=32, Completed, 
    These patients might switch to dolutegravir-based regimen with compromised NRTIs, which could impair the long-term efficacy of ART. Phase classification: P2 --> P=N/A | N=90 --> 32
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal, Monotherapy:  Dolutegravir monotherapy and weight gain in naive patients with <100,000 copies/ml HIV RNA:an extended follow-up. (Pubmed Central) -  Oct 21, 2022   
    We previously reported our experience in 20 HIV-infected patients, naïve to HAART and with a zenith HIV RNA<100,000 copies/ml, followed at the Infectious Diseases Outpatient Department of G.B. Rossi Hospital in Verona, Italy, who started dolutegravir (DGT) monotherapy after refusing nucleoside reverse transcriptase inhibitors. We now report the results of an extended follow-up of the patients still on dolutegravir monotherapy.
  • ||||||||||  Journal:  Excessive weight gain: current antiretroviral agents in virologically suppressed people with HIV. (Pubmed Central) -  Oct 21, 2022   
    Virologically suppressed, antiretroviral therapy (ART)-experienced PWH switching to TAF/FTC with darunavir/cobicistat (DRV/c), elvitegravir/cobicistat (EVG/c), dolutegravir (DTG), or bictegravir (BIC) were selected...In conclusion, in this study of virologically suppressed, ART-experienced PWH switching to regimens containing TAF/FTC and either DRV/c, EVG/c, DTG or BIC, up to 18% experienced excessive levels of weight gain. However, no statistically significant difference was observed across regimens.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Lower insulin sensitivity in newborns with in utero HIV and antiretroviral exposure who are uninfected in Botswana. (Pubmed Central) -  Oct 15, 2022   
    P4
    While supporting the current transition to DTG-containing ART in resource-limited settings toward the achievement of the UNAIDS' goal of HIV elimination by 2030, our findings suggested that RAL-exposed patients may need a specific monitoring approach either in a stratified or personalized model of third-line ART to ensure the long-term success of DTG-containing regimens. Newborns HEU vs. HUU had lower insulin sensitivity at birth and at 1 month of life, raising potential concern for obesity and other metabolic perturbations later in life for newborns HEU.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    A 3-year Adverse Drug Reactions Analysis of HIV Patients on Dolutegravir-containing Regimens in Ethiopia (Convention Center - Room 6C (6th Floor)) -  Oct 9, 2022 - Abstract #ASTMH2022ASTMH_3144;    
    Next steps: The project used results to recommend a national DTG toxicity study to further assess ADRs and inform ART practices. Continuing this health system strengthening approach is expected to increase ADR awareness and improve vigilance in ADR reporting, further decentralize regional PV centers, increase regular analysis of ADR reports, and lead to timely results dissemination for faster, safer patient care.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD), Vitekta (elvitegravir) / Japan Tobacco, Gilead
    Retrospective data, Journal:  Integrase inhibitors in children and adolescents: clinical use and resistance. (Pubmed Central) -  Oct 5, 2022   
    INI-based regimens were effective and safe for HIV treatment in children and adolescents. Dolutegravir and elvitegravir presented an excellent profile, and most patients achieved and maintained viral suppression.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
    Integrase inhibitors mutational viral load in HIV-infected pregnant women in Argentina () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_350;    
    Conversely, accessory mutations exceed this threshold with higher risk of potential transmission to the newborn. Potential clinical impact on maternal ART and neonatal prophylaxis remains to be determined.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    Osteoporosis among older persons living with HIV in Kenya: baseline results from the BFTAF elderly switch study () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_305;    
    DXA is not readily available in Kenya, and risk calculation without BMD did not identify the majority of participants who qualify for treatment of osteoporosis. Additional data for this population are required on clinical implications of undiagnosed osteoporosis, ARV regimen selection to reduce osteoporosis risk, particularly in populations with widespread use of TDF, and on the impact of investment in osteoporosis screening and treatment, including population-specific risk calculators.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Sleep health of Nigerian adults living with HIV: looking beyond the absence of disease (Virtual) -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_298;    
    PLWHIV report average sleep health scores using validated measures. Age, sleep disturbance, depression and anxiety are significant factors associated with lower sleep health scores and as such, addressing these factors may improve the sleep health of PLWHIV.
  • ||||||||||  Tybost (cobicistat) / Gilead, Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    Abstract withdrawn () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_289;    
    Switching from a previous COBI-including regimen was associated with a significant decrease in TC, LDL-c, and TGL. In the TAF-BR group  a significant ALT increase was observed.
  • ||||||||||  Tybost (cobicistat) / Gilead, Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    With or without TAF? What is the difference? Data from a real-life setting () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_288;    
    Switching from a previous COBI-including regimen was associated with a significant decrease in TC, LDL-c, and TGL. In the TAF-BR group  a significant ALT increase was observed.
  • ||||||||||  efavirenz / Generic mfg.
    HIV resistance patterns in a cohort of adults living with HIV failing first-line efavirenz-based antiretroviral therapy in South Africa () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_245;    
    Despite a small sample size, these insights offer valuable information into the resistance patterns of PLWHIV in South Africa, failing NNRTI-based first-line ART regimens. Cross-resistance within NNRTIs may be more prevalent with doravirine than recorded in previous clinical trials, this potentially compromising their role as an option for patients failing EFV-based regimens, particularly with the introduction of dolutegravir into first-line ART programmes in South Africa.
  • ||||||||||  Pifeltro (doravirine) / Merck (MSD), Tivicay (dolutegravir) / ViiV Healthcare
    Efficacy and safety of dolutegravir and doravirine dual therapy in the context of antiretroviral therapy switch: 48 weeks analysis () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_228;    
    Combination strategies with a good tolerability profile, (Figure 1) (Table 1) a high genetic barrier and also the ability to be administered once-daily should be preferred in a setting such as the current SARS-CoV-2 pandemic. The combination of doravirine together with dolutegravir, a drug characterised by an excellent profile of potency, safety and long-term tolerability, appears to be a potential strategy in the setting of patients who require a regimen which maintains high virological efficacy but reduces long-term toxicity and pharmacological potentials.
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    Real-world study with dolutegravir (DTG) plus rilpivirine (RPV) as STR (JULUCA©) in treatment-experienced HIV patients () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_196;    
    Background: Two-drug regimen (2DR) in naive (DTG + lamivudine (3TC)) and treated-experienced HIV patients (DTG+3TC, DTG+RPV, CAB (cabotegravir)+RPV) have been positioned as another strategy in clinical practice. Switching to DTG plus RPV in STR in treatment-experienced HIV patients is an effectiveness strategy, with a favourable lipid profile, which does not influence the inflammatory markers.
  • ||||||||||  Pifeltro (doravirine) / Merck (MSD)
    Interim doravirine safety results from a pilot switch study for women of childbearing potential in South Africa () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_170;    
    A pilot open-label, single-arm, single-centre, phase III, switch study, recruited 100 HIV-positive ART-experienced women in South Africa, to evaluate viral suppression, tolerability, overall safety, and efficacy of DOR/3TC/TDF... Doravirine-based regimes are an effective, tolerable alternative first-line treatment in WCBP, with improved lipid profile, although potential long-term weight gain needs to be further investigated.